File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Obesity as the key player in the metabolic syndrome
  • Basic View
  • Metadata View
  • XML View
TitleObesity as the key player in the metabolic syndrome
 
AuthorsLam, KSL
Xu, A
Wat, NMS
Tso, AWK
Ip, MSM
 
KeywordsMetabolic syndrome
Chinese
Obesity
Adiponectin
C-reactive protein
 
Issue Date2004
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ics
 
CitationAtherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium, Kyoto, Japan, 28 September–2 October 2003. In International Congress Series, 2004, v. 1262, p. 542-545 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ics.2003.11.006
 
AbstractMetabolic syndrome is a common cardiovascular risk factor in urbanized areas in China. In Hong Kong, it affects 17.1% of the population, increasing to 21.9% if the lower IOTF Asian cut-off values for central obesity were used. This is probably related to the increasing prevalence of excess adiposity. Epidemiological studies, cross-sectional and prospective, suggest that obesity plays a key role in metabolic syndrome in the Chinese, although other factors, such as genetic causes, may also enhance its development. Recent data, including those from Hong Kong and Taiwan, suggest that the adipocytokines, especially adiponectin, provide important links between obesity and various components of metabolic syndrome, through effects on insulin sensitivity, fatty acid synthesis and oxidation, nitric oxide production and inflammatory responses. Raised levels of C-reactive protein, a marker of low-grade chronic inflammation, are independently associated with obesity and predict the development of diabetes in the Chinese. Increased fat in the upper airway also predisposes to obstructive sleep apnea (OSA), sympathetic activation and insulin resistance, accounting for the high prevalence of “Syndrome Z” (metabolic syndrome plus obstructive sleep apnea). Appropriate weight control with regular physical exercise and a healthy diet is, therefore, the best prevention and treatment for metabolic syndrome.
 
ISSN0531-5131
 
DOIhttp://dx.doi.org/10.1016/j.ics.2003.11.006
 
DC FieldValue
dc.contributor.authorLam, KSL
 
dc.contributor.authorXu, A
 
dc.contributor.authorWat, NMS
 
dc.contributor.authorTso, AWK
 
dc.contributor.authorIp, MSM
 
dc.date.accessioned2010-09-06T07:36:22Z
 
dc.date.available2010-09-06T07:36:22Z
 
dc.date.issued2004
 
dc.description.abstractMetabolic syndrome is a common cardiovascular risk factor in urbanized areas in China. In Hong Kong, it affects 17.1% of the population, increasing to 21.9% if the lower IOTF Asian cut-off values for central obesity were used. This is probably related to the increasing prevalence of excess adiposity. Epidemiological studies, cross-sectional and prospective, suggest that obesity plays a key role in metabolic syndrome in the Chinese, although other factors, such as genetic causes, may also enhance its development. Recent data, including those from Hong Kong and Taiwan, suggest that the adipocytokines, especially adiponectin, provide important links between obesity and various components of metabolic syndrome, through effects on insulin sensitivity, fatty acid synthesis and oxidation, nitric oxide production and inflammatory responses. Raised levels of C-reactive protein, a marker of low-grade chronic inflammation, are independently associated with obesity and predict the development of diabetes in the Chinese. Increased fat in the upper airway also predisposes to obstructive sleep apnea (OSA), sympathetic activation and insulin resistance, accounting for the high prevalence of “Syndrome Z” (metabolic syndrome plus obstructive sleep apnea). Appropriate weight control with regular physical exercise and a healthy diet is, therefore, the best prevention and treatment for metabolic syndrome.
 
dc.description.otherAtherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium, Kyoto, Japan, 28 September–2 October 2003. In International Congress Series, 2004, v. 1262, p. 542-545
 
dc.identifier.citationAtherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium, Kyoto, Japan, 28 September–2 October 2003. In International Congress Series, 2004, v. 1262, p. 542-545 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ics.2003.11.006
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.ics.2003.11.006
 
dc.identifier.epage545
 
dc.identifier.hkuros91114
 
dc.identifier.issn0531-5131
 
dc.identifier.openurl
 
dc.identifier.spage542
 
dc.identifier.urihttp://hdl.handle.net/10722/77845
 
dc.identifier.volume1262
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ics
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofInternational Congress Series
 
dc.rightsInternational Congress Series. Copyright © Elsevier BV.
 
dc.subjectMetabolic syndrome
 
dc.subjectChinese
 
dc.subjectObesity
 
dc.subjectAdiponectin
 
dc.subjectC-reactive protein
 
dc.titleObesity as the key player in the metabolic syndrome
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lam, KSL</contributor.author>
<contributor.author>Xu, A</contributor.author>
<contributor.author>Wat, NMS</contributor.author>
<contributor.author>Tso, AWK</contributor.author>
<contributor.author>Ip, MSM</contributor.author>
<date.accessioned>2010-09-06T07:36:22Z</date.accessioned>
<date.available>2010-09-06T07:36:22Z</date.available>
<date.issued>2004</date.issued>
<identifier.citation>Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium, Kyoto, Japan, 28 September&#8211;2 October 2003. In International Congress Series, 2004, v. 1262, p. 542-545</identifier.citation>
<identifier.issn>0531-5131</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/77845</identifier.uri>
<description.abstract>Metabolic syndrome is a common cardiovascular risk factor in urbanized areas in China. In Hong Kong, it affects 17.1% of the population, increasing to 21.9% if the lower IOTF Asian cut-off values for central obesity were used. This is probably related to the increasing prevalence of excess adiposity. Epidemiological studies, cross-sectional and prospective, suggest that obesity plays a key role in metabolic syndrome in the Chinese, although other factors, such as genetic causes, may also enhance its development. Recent data, including those from Hong Kong and Taiwan, suggest that the adipocytokines, especially adiponectin, provide important links between obesity and various components of metabolic syndrome, through effects on insulin sensitivity, fatty acid synthesis and oxidation, nitric oxide production and inflammatory responses. Raised levels of C-reactive protein, a marker of low-grade chronic inflammation, are independently associated with obesity and predict the development of diabetes in the Chinese. Increased fat in the upper airway also predisposes to obstructive sleep apnea (OSA), sympathetic activation and insulin resistance, accounting for the high prevalence of &#8220;Syndrome Z&#8221; (metabolic syndrome plus obstructive sleep apnea). Appropriate weight control with regular physical exercise and a healthy diet is, therefore, the best prevention and treatment for metabolic syndrome.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/ics</publisher>
<relation.ispartof>International Congress Series</relation.ispartof>
<rights>International Congress Series. Copyright &#169; Elsevier BV.</rights>
<subject>Metabolic syndrome</subject>
<subject>Chinese</subject>
<subject>Obesity</subject>
<subject>Adiponectin</subject>
<subject>C-reactive protein</subject>
<title>Obesity as the key player in the metabolic syndrome</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0531-5131&amp;volume=1262&amp;spage=542&amp;epage=5&amp;date=2004&amp;atitle=Obesity+as+the+key+player+in+the+metabolic+syndrome</identifier.openurl>
<identifier.doi>10.1016/j.ics.2003.11.006</identifier.doi>
<identifier.hkuros>91114</identifier.hkuros>
<identifier.volume>1262</identifier.volume>
<identifier.spage>542</identifier.spage>
<identifier.epage>545</identifier.epage>
<publisher.place>Netherlands</publisher.place>
<description.other>Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium, Kyoto, Japan, 28 September&#8211;2 October 2003. In International Congress Series, 2004, v. 1262, p. 542-545</description.other>
</item>